Next Century Growth Investors LLC Has $14.09 Million Position in Artivion, Inc. (NYSE:AORT)

Next Century Growth Investors LLC grew its position in shares of Artivion, Inc. (NYSE:AORT - Free Report) by 29.7% during the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 492,653 shares of the company's stock after purchasing an additional 112,918 shares during the quarter. Next Century Growth Investors LLC owned 1.18% of Artivion worth $14,085,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Smartleaf Asset Management LLC grew its holdings in shares of Artivion by 236.7% in the 4th quarter. Smartleaf Asset Management LLC now owns 1,118 shares of the company's stock worth $32,000 after acquiring an additional 786 shares during the last quarter. R Squared Ltd purchased a new stake in Artivion during the fourth quarter valued at about $39,000. Arcadia Investment Management Corp MI acquired a new stake in shares of Artivion during the fourth quarter valued at approximately $43,000. Venturi Wealth Management LLC purchased a new stake in shares of Artivion in the 4th quarter valued at approximately $78,000. Finally, GAMMA Investing LLC boosted its stake in Artivion by 21.8% in the 4th quarter. GAMMA Investing LLC now owns 2,772 shares of the company's stock worth $79,000 after purchasing an additional 497 shares during the period. Institutional investors own 86.37% of the company's stock.

Artivion Stock Down 0.5 %

Shares of AORT stock traded down $0.12 on Tuesday, hitting $23.02. The company's stock had a trading volume of 283,203 shares, compared to its average volume of 293,297. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.88 and a quick ratio of 1.33. The stock has a market capitalization of $982.49 million, a price-to-earnings ratio of -1,150.75 and a beta of 1.65. Artivion, Inc. has a fifty-two week low of $19.36 and a fifty-two week high of $32.33. The firm's fifty day moving average price is $25.66 and its 200-day moving average price is $27.47.

Remove Ads

Artivion (NYSE:AORT - Get Free Report) last issued its quarterly earnings data on Monday, February 24th. The company reported ($0.39) EPS for the quarter, missing analysts' consensus estimates of $0.12 by ($0.51). The company had revenue of $97.31 million for the quarter, compared to analyst estimates of $100.82 million. Artivion had a negative net margin of 0.22% and a positive return on equity of 5.15%. Research analysts anticipate that Artivion, Inc. will post 0.37 EPS for the current year.

Insider Activity

In other news, SVP Jean F. Holloway sold 5,335 shares of the company's stock in a transaction dated Monday, February 24th. The shares were sold at an average price of $27.31, for a total transaction of $145,698.85. Following the completion of the transaction, the senior vice president now owns 149,799 shares of the company's stock, valued at approximately $4,091,010.69. This represents a 3.44 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO James P. Mackin sold 42,156 shares of Artivion stock in a transaction dated Monday, February 24th. The stock was sold at an average price of $27.31, for a total value of $1,151,280.36. Following the sale, the chief executive officer now directly owns 663,882 shares in the company, valued at approximately $18,130,617.42. This trade represents a 5.97 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 90,799 shares of company stock valued at $2,356,223. 8.10% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

A number of research analysts have recently weighed in on AORT shares. Needham & Company LLC lowered their price target on Artivion from $34.00 to $32.00 and set a "buy" rating on the stock in a report on Tuesday, February 25th. Stifel Nicolaus reduced their price target on shares of Artivion from $33.00 to $30.00 and set a "buy" rating for the company in a research report on Tuesday, February 25th. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, Artivion currently has a consensus rating of "Buy" and a consensus target price of $31.40.

Artivion Profile

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.